Antibe Therapeutics has signed a licensing and distribution agreement with Laboratoires Acbel for the drug ATB-346 in Greece, Romania, Serbia, Bulgaria, Albania, Algeria and Jordan.

Anti-inflammatory drug ATB-346 has been designed to spare the gastrointestinal tract of the ulcers and bleeding normally associated with non-steroidal anti-inflammatory drugs (NSAIDs).

As part of a recent Phase II clinical trial, the drug was found to be effective in reducing pain associated with osteoarthritis of the knee.

Antibe Therapeutics CEO Dan Legault said: “We are delighted to have concluded this agreement with Acbel.

"By delivering on our regional licensing strategy, Antibe has obtained non-dilutive funds that can be immediately deployed for our ongoing clinical trials.

"By delivering on our regional licensing strategy, Antibe has obtained non-dilutive funds that can be immediately deployed for our ongoing clinical trials."

“Of perhaps greater importance, this agreement represents an important validation of our drug development programme and its market value by a leading regional pharmaceutical company well versed in the NSAID market.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Antibe will now initiate a placebo-controlled, dose-ranging study to determine the go-to-market dose, and an active comparator trial to demonstrate GI safety.

Under the 30-year agreement, the company will receive an upfront, non-dilutive payment of $1.1m and a 5% royalty on net sales of ATB-346.

At present, Antibe is developing two other therapeutic candidates ATB-352 and ATB-340.

ATB-352 is a non-addictive analgesic and is used to treat severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.